{"id":"W2796046569","doi":"10.1200/jco.2017.35.15_suppl.tps4143","title":"Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC): KEYNOTE-240.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Sorafenib; Medicine; Pembrolizumab; Placebo; Internal medicine; Adverse effect; Hepatocellular carcinoma; Response Evaluation Criteria in Solid Tumors; Oncology; Clinical trial; Surgery; Cancer; Phases of clinical research; Immunotherapy; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00289466,0.002592833,0.003039878,0.0005735127,0.000613044,0.001725398,0.001463681,0.002483726,0.02097179],"category_scores_gemma":[0.002536921,0.001059013,0.002258806,0.0004944472,0.001387069,0.001854392,0.0006935083,0.005170941,0.003277664],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001169801,"about_ca_system_score_gemma":0.001947115,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001272084,"about_ca_topic_score_gemma":0.003075365,"domain_scores_codex":[0.9992375,0.000389332,0.00003161864,0.0001412477,0.0000562463,0.0001440742],"domain_scores_gemma":[0.9986142,0.0003399234,0.0003264582,0.0001088641,0.00008721295,0.0005232799],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.985611,0.006542925,0.0001819083,0.0002800724,0.0004233811,0.00002078547,0.00002176718,0.0001868515,0.001235127,0.00008217153,0.001209925,0.004204242],"study_design_scores_gemma":[0.9666367,0.03162168,0.0005727238,0.00001868427,0.0001754094,0.00001966499,0.00001126965,0.0002563691,0.0001332678,0.000139049,0.0004059958,0.000009242213],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.955353,0.004670314,0.001542068,0.002350009,0.002334422,0.02000243,0.006201524,0.0006177402,0.006928398],"genre_scores_gemma":[0.9528303,0.00259644,0.003136192,0.004394158,0.001024442,0.02196073,0.004181613,0.000111425,0.009764766],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02097179,"threshold_uncertainty_score":0.07015759,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2064633325214666,"score_gpt":0.4643588554910116,"score_spread":0.257895522969545,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}